File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Galactosamine-induced fulminant liver failure - Observation in a porcine model

TitleGalactosamine-induced fulminant liver failure - Observation in a porcine model
Authors
Issue Date2002
PublisherElsevier (Singapore) Pte Ltd, Hong Kong Branch. The Journal's web site is located at http://www.elsevier.com/wps/find/journaldescription.cws_home/708511/description#description
Citation
Asian Journal Of Surgery, 2002, v. 25 n. 1, p. 73-79 How to Cite?
AbstractFulminant hepatic failure can only be treated successfully by liver transplantation, which, however, is not always available. To "bridge" the patient with fulminant hepatic failure until a liver graft is available, various forms of liver support devices had been designed but they were not uniformly successful. To prove the efficacy of a liver support device for fulminant hepatic failure, testing in an animal model is necessary. We attempted to induce a pig model with fulminant hepatic failure by administering galactosamine into pigs and reported the observation. Three pigs were given a dose of 0.5 gm/kg of galactosamine and five pigs were given 1 gm/kg of galactosamine. One pig receiving 0.5 gm/kg galactosamine survived after manifestation of liver failure, while all the other pigs died. The two pigs receiving 0.5 gm/kg galactosamine survived longer than the five pigs receiving 1 gm/kg galactosamine. Before death, a significant elevation of parenchymal liver enzymes, lactate dehydrogenase, bilirubin, bile acid, ammonia, tumour necrosis factor-α, activated clotting time, a decrease of platelet concentration, ketone bodies ratio, blood glucose and plasma albumin, and serious impairment of indocyanine green clearance were indicated. At post-mortem, severe liver necrosis was observed. The model may be suitable for testing the efficacy of liver support device for fulminant hepatic failure, preferably 24-48 hours after administration of galactosamine.
Persistent Identifierhttp://hdl.handle.net/10722/88375
ISSN
2015 Impact Factor: 0.912
2015 SCImago Journal Rankings: 0.427
References

 

DC FieldValueLanguage
dc.contributor.authorHo, DWYen_HK
dc.contributor.authorLam, DKen_HK
dc.contributor.authorChen, YBen_HK
dc.contributor.authorTo, Jen_HK
dc.contributor.authorNg, IOLen_HK
dc.contributor.authorFan, STen_HK
dc.date.accessioned2010-09-06T09:42:33Z-
dc.date.available2010-09-06T09:42:33Z-
dc.date.issued2002en_HK
dc.identifier.citationAsian Journal Of Surgery, 2002, v. 25 n. 1, p. 73-79en_HK
dc.identifier.issn1015-9584en_HK
dc.identifier.urihttp://hdl.handle.net/10722/88375-
dc.description.abstractFulminant hepatic failure can only be treated successfully by liver transplantation, which, however, is not always available. To "bridge" the patient with fulminant hepatic failure until a liver graft is available, various forms of liver support devices had been designed but they were not uniformly successful. To prove the efficacy of a liver support device for fulminant hepatic failure, testing in an animal model is necessary. We attempted to induce a pig model with fulminant hepatic failure by administering galactosamine into pigs and reported the observation. Three pigs were given a dose of 0.5 gm/kg of galactosamine and five pigs were given 1 gm/kg of galactosamine. One pig receiving 0.5 gm/kg galactosamine survived after manifestation of liver failure, while all the other pigs died. The two pigs receiving 0.5 gm/kg galactosamine survived longer than the five pigs receiving 1 gm/kg galactosamine. Before death, a significant elevation of parenchymal liver enzymes, lactate dehydrogenase, bilirubin, bile acid, ammonia, tumour necrosis factor-α, activated clotting time, a decrease of platelet concentration, ketone bodies ratio, blood glucose and plasma albumin, and serious impairment of indocyanine green clearance were indicated. At post-mortem, severe liver necrosis was observed. The model may be suitable for testing the efficacy of liver support device for fulminant hepatic failure, preferably 24-48 hours after administration of galactosamine.en_HK
dc.languageengen_HK
dc.publisherElsevier (Singapore) Pte Ltd, Hong Kong Branch. The Journal's web site is located at http://www.elsevier.com/wps/find/journaldescription.cws_home/708511/description#descriptionen_HK
dc.relation.ispartofAsian Journal of Surgeryen_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshDisease Models, Animalen_HK
dc.subject.meshDose-Response Relationship, Drugen_HK
dc.subject.meshDrug Costsen_HK
dc.subject.meshGalactosamine - administration & dosage - economicsen_HK
dc.subject.meshLiver Failure, Acute - chemically induced - metabolism - pathologyen_HK
dc.subject.meshSwineen_HK
dc.titleGalactosamine-induced fulminant liver failure - Observation in a porcine modelen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1015-9584&volume=25&spage=73&epage=79&date=2002&atitle=Galactosamine-induced+fulminant+liver+failure+-+observation+in+a+porcine+modelen_HK
dc.identifier.emailNg, IOL: iolng@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityNg, IOL=rp00335en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid17585450-
dc.identifier.scopuseid_2-s2.0-0036194252en_HK
dc.identifier.hkuros83138en_HK
dc.identifier.hkuros68799-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036194252&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume25en_HK
dc.identifier.issue1en_HK
dc.identifier.spage73en_HK
dc.identifier.epage79en_HK
dc.publisher.placeHong Kongen_HK
dc.identifier.scopusauthoridHo, DWY=7402971906en_HK
dc.identifier.scopusauthoridLam, DK=36939420700en_HK
dc.identifier.scopusauthoridChen, YB=7601423819en_HK
dc.identifier.scopusauthoridTo, J=36641520100en_HK
dc.identifier.scopusauthoridNg, IOL=7102753722en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats